Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Year: 2019
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Georgina V Long, Robyn P M Saw, Serigne Lo, Omgo E Nieweg, Kerwin F Shannon, Maria Gonzalez, Alexander Guminski, Jenny H Lee, Hansol Lee, Peter M Ferguson, Robert V Rawson, James S Wilmott, John F Thompson, Richard F Kefford, Sydney Ch'ng, Jonathan R Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J Spillane, Richard A Scolyer, Alexander M Menzies
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W2947338182
